Mylan Settles Dispute Over Generic Orapred ODT

Law360, New York (October 10, 2012, 3:31 PM EDT) -- Mylan Inc. has entered into a licensing agreement that will allow it to sell its generic version of anti-inflammatory Orapred ODT, ending a patent infringement dispute with rivals Shionogi Pharma Inc. and Cima Labs Inc., the company announced Tuesday.

According to Mylan’s statement, the companies have reached a settlement ending their litigation over the drug and allowing Mylan to sell generic prednisolone sodium phosphate orally disintegrating tablets in three different dosage strengths, beginning April 1, 2014. The rest of the terms of the settlement were confidential,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.